Acadia Pharma (ACAD) Tops Q3 EPS by 6c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $21.62 +0.09%
Revenue Growth %: +12.1%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: +12.1%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q3 EPS of $0.20, $0.06 better than the analyst estimate of $0.14. Revenue for the quarter came in at $250.4 million versus the consensus estimate of $248.6 million.
GUIDANCE:
Acadia Pharma sees FY2024 revenue of $940-960 million, versus the consensus of $952.5 million.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kalshi in early talks for IPO - The Information
- FedEx (FDX) PT Lowered to $424 at Bernstein SocGen Group
- Huntington Ingalls wins $418M Navy contract
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
